Non-small cell lung cancer, second line
NWT-4471 with docetaxel against docetaxel alone in previously treated non-small cell lung cancer. Sponsor: Northwind Therapeutics (fictional), Oncology.
Key risk indicators watch each site, as its data arrives, for the risks on this study's Risks tab under Design and risks. A problem shows at the site before it reaches the study's KPIs or QTLs.
Thresholds by country
A country's threshold is tighter than the default only where a sourced country risk supports it: five here. Everywhere else the default applies, because no difference between countries was found.
| KRI | Default | United States | United Kingdom | Spain | Poland | Turkey | India | Sites over |
|---|---|---|---|---|---|---|---|---|
| Site activation overdueDays a site's activation runs past the end of its country's planned start-up window | Above 30 days | 0 days | Default | Default | Default | 0 days | 14 days | 0 of 159 |
| Screen failure above the study'sPercentage points by which a site's screen failure exceeds the study's own, once it has screened enough patients | Above +15 points | Default | Default | Default | Default | Default | Default | 1 of 3 |
| Data entry lagMedian days from a patient's visit to its data being entered, over the last three months | Above 7 days | Default | Default | Default | Default | Default | Default | 10 of 89 |
| Queries open over 30 daysShare of a site's open data queries that have been open for more than 30 days, over the last three months | Above 20% | Default | Default | Default | Default | Default | Default | 7 of 89 |
| Important protocol deviationsImportant protocol deviations per hundred patient-months in the study at the site, so long and short studies compare fairly | Above 2 | Default | Default | Default | Default | Default | Default | 5 of 18 |
| Consent findingsConsent findings (missing, outdated or incomplete consent records) per hundred patients consented at the site | Above 5 | Default | Default | Default | Default | Default | 0 | Too early |
| Study drug at the siteWeeks of study drug held at the site, resupplied early below the threshold | Below 4 weeks | Default | Default | Default | Default | 8 weeks | Default | Not in the data |
| Enrolment against the diversity planShare of the enrolment goal for each under-represented group met so far, against the study's diversity action plan | Below 80% | Default | – | – | – | – | – | Not in the data |
- United States, site activation overdue: 0 days. US sites are activated slowly after the first: 309 days to activate 75% of US sites against 34 to 126 days elsewhere. A late US site is escalated at once. (register PM-03)
- Turkey, site activation overdue: 0 days. Turkey's ethics committees fell from 145 to 49 in 2024, and nobody has measured the delay that followed. A late Turkish site is escalated at once. (register RW-05)
- Turkey, study drug at the site: 8 weeks. Turkey has had repeated medicine shortages under its fixed pharmaceutical exchange rate (645 products short in November 2021), so sites hold a larger buffer. (register RW-07)
- India, site activation overdue: 14 days. Start-up time in India is unmeasured beyond the statutory 90 working days, so a late site is escalated after two weeks rather than a month. (register PM-04)
- India, consent findings: 0. India requires an audio-visual record of consent from vulnerable participants in trials of new drugs. Any missing record is a finding to act on, not a rate to watch. (register RW-03)
Sites over a threshold
19 out of 159 sites are over at least one threshold, most first. Each is a prompt for the CRA to look, not a finding; the Sites tab shows whether the same sites are behind on recruitment.
| Site | Over |
|---|---|
| 301-UK-15, LondonUnited Kingdom | Data entry lag: 8.7 days against 7 daysQueries open over 30 days: 37.3% against 20%Important protocol deviations: 5.6 against 2 |
| 301-PL-17, OlsztynPoland | Data entry lag: 11.6 days against 7 daysQueries open over 30 days: 29% against 20% |
| 301-TR-07, İzmirTurkey | Screen failure above the study's: +28 points against +15 pointsData entry lag: 8.8 days against 7 days |
| 301-ES-02, MadridSpain | Important protocol deviations: 4.1 against 2 |
| 301-ES-11, Santiago de CompostelaSpain | Queries open over 30 days: 28.3% against 20% |
| 301-ES-12, MálagaSpain | Data entry lag: 9 days against 7 days |
| 301-ES-16, ZaragozaSpain | Data entry lag: 7.2 days against 7 days |
| 301-ES-30, AlicanteSpain | Queries open over 30 days: 33.7% against 20% |
| 301-ES-31, ZaragozaSpain | Data entry lag: 7.6 days against 7 days |
| 301-ES-33, SalamancaSpain | Data entry lag: 14.2 days against 7 days |
| 301-IN-12, LucknowIndia | Queries open over 30 days: 32% against 20% |
| 301-TR-09, AntalyaTurkey | Data entry lag: 7.1 days against 7 days |
| 301-UK-02, NewcastleUnited Kingdom | Queries open over 30 days: 20.3% against 20% |
| 301-UK-14, ManchesterUnited Kingdom | Important protocol deviations: 5.9 against 2 |
| 301-UK-16, CardiffUnited Kingdom | Important protocol deviations: 3.7 against 2 |
| 301-UK-24, LiverpoolUnited Kingdom | Queries open over 30 days: 21.3% against 20% |
| 301-UK-25, NottinghamUnited Kingdom | Data entry lag: 7.1 days against 7 days |
| 301-US-21, HoustonUnited States | Important protocol deviations: 5.3 against 2 |
| 301-US-29, AtlantaUnited States | Data entry lag: 7.7 days against 7 days |
Sources: epiClinical synthetic KRI data, in which levels follow each site's own facts (such as coordinator time), never its country. Readings marked too few wait until a site has enough patients; drug supply and diversity come from systems the synthetic data does not include.